Immune-mediated mechanisms of vegf-A165 alternative splicing in angiogenesis in the context of advanced aging
Active Grant Awarded Last action
- Award ID
- R01HL181104
- Recipient
-
Ocean State Research Institute Inc. UEI YZWJABL7PW69
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $514,340
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 4% complete
- Place of performance
- Providence, RI 02908, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, National Heart, Lung, and Blood Institute awarded Ocean State Research Institute Inc. a grant of $514,340 on September 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will investigate the immune-mediated mechanisms of VEGF-A165 alternative splicing in peripheral artery disease in the context of advanced aging, with the stated aim of reprogramming macrophages to promote angiogenesis in ischemic tissue. The abstract reports results from a femoral artery ligation mouse model comparing advanced-aged (2-year-old) and young (12-week-old) mice, including reduced pro-angiogenic VEGF-A165a expression and increased VEGF-A165b and IL-1B in aged animals on day 3 after surgery. The source identifies the research focus on splicing regulation through spliceosomes, including reductions in SRPK1 and SRSF1 and increased WNT5A in aged mice. The award's period of performance runs through May 31, 2031, and the place of performance is Providence, Rhode Island 02908. The assistance type is a grant. The source does not identify sub-recipients for this award.
Description
- Abstract
- Abstract: peripheral artery disease (pad) is a result of atherosclerosis, a major health problem worldwide, associated with narrowed arteries and reduced blood flow to the lower extremities. Combining aging (>65 years) and diabetes mellitus (DM) represents the most significant risk factor from patients to develop critical limb ischemia, a severe form of pad, potentially leading to limb amputation. In addition to medication management, mechanical revascularization by surgery bypass or angioplasty can apply but not all pad patients are eligible. Thus, new alternative therapeutic strategies are needed. Approaches to leverage key angiogenic molecules like VEGF-a therapy (e.g. gene therapy) have been elusive and unable to fully restore functional vascular network, highlighting the limits in understanding mechanisms of action of VEGF-A165 which can exist in alternative splice variants, proangiogenic (VEGF-A165A) and antiangiogenic (VEGF-A165B). We seek to determine the mechanisms of immune-mediated vascular remodeling associated with VEGF-A165 alternative splicing in pad and in the context of aging with an eye to reprogram macrophages and promote angiogenesis in ischemic tissue. Advanced aged (2-YEAR-old) mice showed severely impaired blood flow recovery compared to young (12-WEEK-old) mice in a femoral artery ligation model of pad with reduced new capillaries/arteries. On day 3 after surgery, proangiogenic VEGF-A165A expression was reduced in aged mice while IL-1Β and VEGF-A165B were significantly increased, suggesting an uncoupling of IL-1Β-proangiogenic VEGF-a signaling and an age-associated VEGF-A165 splice isoform switch. VEGF-A165 splicing is regulated by spliceosomes. We also found reductions in SRPK1 and SRSF1 in aged mice while WNT5A was significantly increased. VEGFR1/2 receptors were also reduced in advanced aged mice. Interestingly, primary macrophages from aged mice also demonstrated comparable phenotypes in SRPK1, SRSF1 and WNT5A expression. We have then generated new transgenic mice expressing either EXON8A or EXON8B. Our preliminary results demonstrate delayed blood flow recovery in young macrophage VEGF-A165A KO mice while control and macrophage mvegf-A165B KO mice were comparable. Lastly, 52-WEEK-old control and young type 2 DM mice had delayed blood flow recovery, ≈60% and ≈50%, respectively compared to young control. Clinically, elderly patients with type 2 DM are most at risk for pad and CLI. To model this, combining aging and diabetes, leads to a further reduction in blood flow recovery (≈30%), reduced proangiogenic VEGF-a in ischemic tissue while IL1Β was increased. Our investigations will improve understanding of how VEGF-A165 alternative splicing switch occurs, what is the mechanism of action, the importance and expression levels of VEGF isoforms particularly in conditions that lead to pad and age-related diseases.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $350,000 |
Quick answers
Who received award R01HL181104?
R01HL181104 was awarded to Ocean State Research Institute Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 18, 2026.
How much is award R01HL181104 worth?
$514,340 has been obligated on R01HL181104.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award